10-Q quarterly report · filed Oct 30, 2026

Organon & Co (OGN) Q3 2026 10-Q Quarterly Report

Short answer

Organon & Co (OGN) filed its Q3 2026 10-Q quarterly report on Oct 30, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $1.6B (down 1.7% year over year) with net income of $164M.

Q3 2026 key financials · XBRL

Revenue
$1.6B
−1.7% YoY · +1.0% QoQ
Net income
$164M
+2.5% YoY · +51.9% QoQ
Gross margin
55.2%
EPS (diluted)
$0.61
+0.0% YoY · +52.5% QoQ

Source: XBRL data from the Organon & Co (OGN) Q3 2026 10-Q on SEC EDGAR. USD.

Organon & Co Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Revenue $1.574B, down 2% YoY, including approximately $12M favorable foreign exchange impact
  • Quarterly gross margin 61.2% vs 59.6% YoY, based on gross profit of $965M and revenue of $1.574B
  • Best product: Hadlima sales up 35% YoY; worst: Ontruzant sales down 77%
  • Cash $1.46B; nine-month operating cash flow $702M vs $559M YoY
  • Headwinds: supply constraints, Nexplanon demand weakness, VBP expected to continue affecting general medicines for several quarters

Risk Factors

  • Newly added patent risk: four Vtama generic ANDAs filed, targeting twelve or nine Orange Book patents expiring 2036–2039
  • Regulatory risk: SEC investigation into Nexplanon wholesaler sales, following Organon’s October 26, 2025 voluntary disclosure
  • Legal risk: third stockholder derivative suit filed September 19, 2026, adding allegations concerning capital allocation, debt reduction and Nexplanon
  • Operational risk: Samsung returned Ontruzant and Aybintio commercialization rights in specified ex-U.S. markets, with transitions through 2029
  • Financial risk: $8,554 million debt principal, including $3,483 million due in 2028 and average maturity of 3.8 years

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.